Blood-based biomarkers for early diagnosis of Alzheimer's disease: a current systematic review of diagnostic accuracy studies - PubMed
3 hours ago
- #diagnostic-accuracy
- #Alzheimers-disease
- #biomarkers
- Blood-based biomarkers, especially phosphorylated tau (p-tau181, p-tau217) and GFAP, show high diagnostic accuracy for early Alzheimer's disease detection, with AUC values up to 0.93.
- Amyloid-β ratios (Aβ42/Aβ40) offer moderate to high accuracy in preclinical stages, but performance varies across assays, with AUC ranges from 0.69 to 0.94.
- Combining biomarkers, including genetic factors like APOE genotype, improves diagnostic effectiveness over single markers, achieving AUC up to 0.92.
- Challenges include assay variability and lack of standardization, requiring large-scale validation and harmonization for clinical integration.
- Neurofilament light chain (NfL) has moderate diagnostic value (AUC up to 0.79) and is more predictive of disease progression than early diagnosis.